secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001193125-25-177505
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks appoints Ciongoli and Landry to board; Cox resigns; private placement of $4.99M to Ciongoli
--------------------------------------------------------------------------------

- Gregory Ciongoli and Robert E. Landry appointed as directors effective Aug 10, 2025; Ciongoli as Class II, Landry as Class I; both join Audit Committee.
- Troy M. Cox resigned from Board and Audit Committee effective Aug 9, 2025; no disagreement with company.
- Company sold 415,000 shares to Ciongoli at $12.02/share for aggregate $4,988,300 in unregistered private placement.
- Proceeds from private placement will be used for working capital and general corporate purposes; closing expected Aug 12, 2025.
- Press release highlights upcoming Q4 2025 data readout for HERIZON-GEA-01 and recent zanidatamab approvals in US, Europe, and China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525177505/0001193125-25-177505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525177505/d86037d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-177505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer